Phase 1/2 single-agent study of Voruciclib in a combination with venetoclax (Venclexta) in relapsed/refractory B lymphocyte malignancies and subsequently

Trial Profile

Phase 1/2 single-agent study of Voruciclib in a combination with venetoclax (Venclexta) in relapsed/refractory B lymphocyte malignancies and subsequently

Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Venetoclax (Primary) ; Voruciclib (Primary)
  • Indications B-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 08 Nov 2017 MEI Pharma Expecting to initiate this trial in the second quarter of 2018, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top